Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia

Publication Date: March 1, 2004

The adoption of Gleevec, a pioneering drug in the treatment of CML, highlights challenges and opportunities in bringing drugs treating rare diseases to market.

Executive Summary
Full Report

Back To Publications

On January 18, 2011, we changed the name of our organization to NEHI. All publications issued prior to that date contain our previous name, New England Healthcare Institute.